MedTrace Logo

Safety and Tolerability of Varenicline in Schizophrenia (SATOVA)

NCT00702793 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2017-11-29

No results posted yet for this study

Summary

This is a 15 week trial to determine (1) the safety and tolerability of varenicline when used for smoking cessation/reduction in individuals with schizophrenia; (2) if treatment with varenicline affects the symptoms of schizophrenia.

Conditions

Interventions

DRUG

Varenicline

Varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily through week 12. Administration of twice daily dosing should be at least 8 hours apart.

Sponsors & Collaborators

  • Provincial Health Services Authority

    collaborator OTHER

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Ric M. Procyshyn, Ph.D · University of British Columbia

  • Alasdair Barr, Ph.D · University of British Columbia

  • Joyce Coutts, MD · Forensic Psychiatric Institute

  • Sean Flynn, MD · University of British Columbia

  • Chris Schenk, MD · Riverview Hospital

  • William Honer, MD · University of British Columbia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2012-05-31
Completion
2012-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00702793 on ClinicalTrials.gov